The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients.

MiR‐125b relative expression at W0, W4, W12, and W24 was 2.420 (1.578‐3.695), 1.937 (1.095‐2.603), 1.612 (0.798‐2.338), and 1.417 (0.676‐2.220), respectively, which also displayed a decreasing trend ( P < .001) (Figure 2C ). 3.5 Correlation of baseline miR‐125a and miR‐125b with clinical response to IFX at W24 in RA patients RA patients were divided into responders (n = 69; 71.9%) and non‐responders (n = 27; 28.1%) based on clinical response status at W24.

also in 47,180 other papers